Core Viewpoint - STRATA Skin Sciences, Inc. has filed a Form 25 with the SEC to deregister its common stock and has suspended trading on Nasdaq, indicating a strategic shift to "go dark" and reduce compliance costs [1][2]. Group 1: Company Actions - The company plans to file a Form 15 around March 2, 2026, to terminate the registration of its common stock and suspend reporting obligations under the Exchange Act [1]. - The delisting from Nasdaq is expected to save significant time and money in general and administrative expenses, allowing the company to focus on its operating plan and customer needs [2]. Group 2: Financial Position - STRATA finished the 2025 fiscal year with a strong balance sheet, including $8 million in cash, indicating financial stability [3]. - The company is engaging with its lender to adjust loan terms to reflect its new status as a private company, with management confident in a favorable outcome [3]. Group 3: Strategic Focus - The decision to "go dark" is aimed at minimizing management distractions related to compliance, allowing for a greater focus on long-term value creation and market expansion [2][3]. - The company anticipates leveraging changes in CPT codes to enhance its market position for XTRAC® excimer laser and TheraclearX® users, which could drive future growth [3].

Core Insights - STRATA Skin Sciences, Inc. participated in the 2025 Ibero-Latin American Congress of Dermatology (TeraCILAD) showcasing its XTRAC® excimer laser and TheraclearX® acne therapy system [1][4] - By the end of 2025, STRATA expects to have over 12 new recurring TheraclearX® accounts in Mexico, indicating a growing adoption of this acne treatment by dermatologists [1][5] Conference Presentations & Clinical Insights - Dr. Melissa Lomeli presented her experience with TheraclearX® at TeraCILAD, highlighting the potential for acne improvement in just one 20-minute session [3] - Dr. Henry Lim discussed the efficacy of XTRAC 308 nm Excimer Laser Therapy for treating vitiligo, psoriasis, and atopic dermatitis [3] Market Context - STRATA engaged with leading dermatologists at TeraCILAD to present the clinical performance of its technologies, with XTRAC® recognized for treating inflammatory and autoimmune skin disorders and TheraclearX® gaining traction as a non-pharmaceutical acne solution [4][7] - The interest from dermatologists in effective, non-systemic treatment options was evident, reinforcing the value of STRATA's technologies in improving patient outcomes [5] Strategic Outlook - STRATA aims to expand access to advanced dermatology solutions across Latin America and globally, with a focus on engaging key opinion leaders and growing recurring revenue opportunities through device-based therapies [6][8] - The company anticipates that fully developed partner clinics could generate upwards of $30,000 in annual revenue per clinic from TheraclearX® placements [6]

Core Insights - STRATA Skin Sciences, Inc. has highlighted a recent study demonstrating the efficacy of its 308nm Excimer laser combined with a JAK inhibitor for treating localized non-segmental vitiligo, showing superior results compared to monotherapy [1][2][4] Study Findings - The study involved 251 patients and revealed five key findings: 1. Mechanistic synergy between JAK inhibitors and Excimer laser therapy [7] 2. A 14.20% higher repigmentation rate with the combination therapy [7] 3. A 100% significant efficacy rate after 52 weeks of treatment [7] 4. At one-year follow-up, the combination group showed 96.5% pigmentation stability and an 8.8% relapse rate [7] 5. The treatment exhibited an excellent safety profile with no serious adverse events [7] Clinical Validation - The study adds to over 400 existing studies validating the 308nm Excimer laser as a cornerstone therapy for various inflammatory and autoimmune skin diseases [3][4] - The combination therapy is positioned as a personalized medicine approach, allowing for tailored treatment based on laser exposure duration and dosage [3] Company Strategy - The company is pursuing expanded reimbursement for its treatments, leveraging the strong clinical evidence from the recent study [3][4] - STRATA continues to work with regulators to enhance access to its treatment modalities by early 2026 [3]